공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

원내감염증 검사 시장 : 세계 산업 동향, 점유율, 규모, 성장률, 기회, 예측(2021-2026년)

Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

리서치사 IMARC Services Private Limited
발행일 2021년 04월 상품 코드 999773
페이지 정보 영문 105 Pages
가격
US $ 2,299 ₩ 2,638,000 PDF (Single User License)
US $ 3,399 ₩ 3,900,000 PDF (5 User License)
US $ 4,499 ₩ 5,162,000 PDF (Corporate License)


원내감염증 검사 시장 : 세계 산업 동향, 점유율, 규모, 성장률, 기회, 예측(2021-2026년) Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
발행일 : 2021년 04월 페이지 정보 : 영문 105 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 원내감염증 검사 시장 규모는 2020년에 73억 2,000만 달러 가치에 달했습니다. 원내감염증(HAI)은 병원 및 진료소에서 이환하는 질병입니다. 요양시설, 재활치료 센터, 병원, 기타 임상 환경 주변에서도 이러한 질병에 걸릴 가능성이 있습니다. 대부분의 사람은 집중치료실(ICU) 및 응급실(ER)에 있을 때 HAI에 감염합니다. 일반적으로 이 질병의 잠복 기간은 개인이 입원하고 나서 48시간부터 4일간으로 다릅니다. 원내감염증 원인의 배후에 있는 주요 이유는 내부 스탭에 의한 병원 환경에서 적절한 위생 상태의 결여입니다. 또 하나의 이유는 표준 이하의 메인터넌스, 병원 스탭에 의한 현황에 대한 자기만족 및 다제내성균(MDRO)의 증가일 가능성이 있습니다. 가장 일반적으로 발생하는 원내감염에는 폐렴, 일차성 혈류감염, 요로감염 등이 있습니다. 많은 경우, 이 원내감염은 환자 자신의 마이크로바이옴에 기인하는 경우도 있습니다. 이것은 보호 피부층이 잠재적 위협과 접촉하며, 특히 외과수술 후에 감염을 일으키는 경우에 발생합니다.

원내감염증 검사 시장은 현재 두 자릿수의 성장률을 나타내고 있습니다. 인구의 증가와 헬스케어 인프라의 현대화에 의해 세계에서 의료시설 수가 대폭 증가하고 있습니다. 이것에 의해 HAI의 발생률이 상승하며, 원내감염에 의한 질병 검사의 수요가 높아지고 있습니다. 또한 첨단 기술과 과학적 혁신에 의해 마이크로어레이, 중합효소 연쇄 반응(PCR), 실시간 로케이션 시스템(RTLS), 고상 하이브리다이제이션 등의 HAI를 예방, 진단, 감시하기 위한 다양한 기술이 시장에서 이용 가능해졌습니다. RTLS 등의 기술에 의해 HAI가 환자와 스탭 양측에 확산되는 것을 간단하게 막을 수 있습니다. 환자 사이에 HAI의 인식이 높아지고 있는 것과 HAI의 발생률이 높은 병원에 페널티를 부과하는 규제를 제정하는 정부 등도 시장 성장을 촉진하고 있는 요인입니다. 세계의 원내감염증 검사 시장은 향후 5년간 강력한 성장을 보일 것으로 예상되고 있습니다.

세계의 원내감염증 검사 시장에 대해 조사했으며, 업계 동향, 시장 예측, 적응증·지역별 시장 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서문

제2장 범위와 조사 방법

제3장 개요

제4장 서론

제5장 세계의 원내감염증 검사 시장

  • 시장 개요
  • 시장 실적
  • COVID-19의 영향
  • 적응증별 시장 세분화
  • 지역별 시장 세분화
  • SWOT 분석
    • 개요
    • 강점
    • 약점
    • 시장 기회
    • 위협
  • 밸류체인 분석
  • Porter의 산업 분석
  • 가격 분석

제6장 적응증별 시장 세분화

  • UTI(요로감염증)
  • SSI(수술 부위 감염증)
  • 폐렴
  • 균혈증
  • MRSA(메티실린 내성 황색 포도 구균)
  • 기타

제7장 지역별 시장 세분화

  • 북미
  • 유럽
  • 아시아태평양
  • 중동·아프리카
  • 라틴아메리카

제8장 경쟁 구도

  • 시장 구조
  • 주요 기업
  • 주요 기업의 개요
    • Abbott Laboratories
    • Alere, Inc.
    • Becton, Dickinson and Company
    • bioMerieux SA
    • F. Hoffmann-La Roche Ltd.
    • Hologic, Inc.
    • QIAGEN
    • Siemens Healthcare
    • Diatherix Laboratories, Inc.
    • Meridian Bioscience, Inc.
    • Thermo Fisher Scientific, Inc.(Life Technologies Corporation)
    • Cepheid, Inc.
KSA 21.04.27

List of Figures

  • Figure 1: Global: Hospital Acquired Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Acquired Disease Testing Market: Sales Value (in Billion US$), 2015-2020
  • Figure 3: Global: Hospital Acquired Disease Testing Market: Breakup by Indication (in %), 2020
  • Figure 4: Global: Hospital Acquired Disease Testing Market: Breakup by Region (in %), 2020
  • Figure 5: Global: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Billion US$), 2021-2026
  • Figure 6: Global: Hospital Acquired Disease Testing Industry: SWOT Analysis
  • Figure 7: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 8: Global: Hospital Acquired Disease Testing Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 10: Global: Hospital Acquired Disease Testing (Urinary Tract Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 11: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 12: Global: Hospital Acquired Disease Testing (Surgical Site Infection) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 13: Global: Hospital Acquired Disease Testing (Pneumonia) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 14: Global: Hospital Acquired Disease Testing (Pneumonia) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 15: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 16: Global: Hospital Acquired Disease Testing (Bloodstream Infections) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 17: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 18: Global: Hospital Acquired Disease Testing (Methicillin-Resistant Staphylococcus Aureus) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 19: Global: Hospital Acquired Disease Testing (Other Indications) Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 20: Global: Hospital Acquired Disease Testing (Other Indications) Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 21: North America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 22: North America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 23: Europe: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 24: Europe: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 25: Asia Pacific: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 26: Asia Pacific: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 27: Middle East and Africa: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 28: Middle East and Africa: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026
  • Figure 29: Latin America: Hospital Acquired Disease Testing Market: Sales Value (in Million US$), 2015 & 2020
  • Figure 30: Latin America: Hospital Acquired Disease Testing Market Forecast: Sales Value (in Million US$), 2021-2026

List of Tables

  • Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2020 and 2026
  • Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2021-2026
  • Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2021-2026
  • Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
  • Table 5: Global: Hospital Acquired Disease Testing Market: Key Players

The global hospital-acquired disease testing market reached a value of US$ 7.32 Billion in 2020. Hospital acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and the emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Another reason can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patients' own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.

The market for hospital acquired disease testing is currently exhibiting double digit growth rates. Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market. Looking forward, IMARC Group expects the global hospital acquired disease testing market to exhibit strong growth during the next five years.

Market Summary:

Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

The competitive landscape of the market has also been examined with some of the key players being Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMerieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.

This report provides a deep insight into the global hospital-acquired disease testing market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the hospital-acquired disease testing market in any manner.

Key Questions Answered in This Report:

  • 1. What is the market size for the global hospital acquired disease testing market?
  • 2. What is the global hospital acquired disease testing market growth?
  • 3. What are the global hospital acquired disease testing market drivers?
  • 4. What are the key industry trends in the global hospital acquired disease testing market?
  • 5. What is the impact of COVID-19 on the global hospital acquired disease testing market?
  • 6. What is the global hospital acquired disease testing market breakup by indication?
  • 7. What are the major regions in the global hospital acquired disease testing market?
  • 8. Who are the key companies/players in the global hospital acquired disease testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Acquired Disease Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Indication
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Indication

  • 6.1 UTI (Urinary Tract Infection)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 SSI (Surgical Site Infection)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Pneumonia
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Bloodstream Infections
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Europe
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Asia Pacific
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Abbott Laboratories
    • 8.3.2 Alere, Inc.
    • 8.3.3 Becton, Dickinson and Company
    • 8.3.4 bioMerieux SA
    • 8.3.5 F. Hoffmann-La Roche Ltd.
    • 8.3.6 Hologic, Inc.
    • 8.3.7 QIAGEN
    • 8.3.8 Siemens Healthcare
    • 8.3.9 Diatherix Laboratories, Inc.
    • 8.3.10 Meridian Bioscience, Inc.
    • 8.3.11 Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
    • 8.3.12 Cepheid, Inc.
Back to Top
전화 문의
F A Q